[Clinical observation on the efficacy and safety of dupilumab in the treatment of moderate to severe atopic dermatitis].

To investigate the clinical efficacy and safety of dupilumab in the treatment of moderate to severe atopic dermatitis (AD) in China. A small sample self-controlled study before and after treatment was conducted to retrospective analysis patients with moderate to severe AD treated with dupilumab in the department of dermatology of the First Affiliated Hospital of Chongqing Medical University from July 2020 to March 2022. Dupilumab 600 mg was injected subcutaneously at week 0, and then 300 mg was injected subcutaneously every 2 weeks. The condition was evaluated by SCORAD(severity scoring of atopic dermatitis), NRS(numerical rating scale), DLQI(dermatology life quality index) and POEM(patient-oriented eczema measure). The improvement of SCORAD, NRS, DLQI and POEM was analyzed by paired test and non-parametric paired Wilcoxon. The results showed that a total of 67 patients with moderate to severe AD received dupilumab treatment, of which 41 patients (the course of treatment was more than 6 weeks) had reduced the severity of skin lesions, improved quality of life and reduced pruritus. A total of 23 patients completed 16 weeks of treatment. At 4, 8, 12 and 16 weeks, SCORAD, NRS, DLQI and POEM decreased compared with the baseline, and the differences were statistically significant. SCORAD (50.13±15.19) at baseline, SCORAD (36.08±11.96)(=6.049,<0.001) at week 4,SCORAD (28.04±11.10)(=10.471,<0.001) at week 8, SCORAD (22.93±9.72)(=12.428,<0.001) at week 12, SCORAD (16.84±7.82)(=14.609,<0.001) at week 16, NRS 7(6,8) at baseline, NRS 4(3,5)(3.861,<0.001) at week 4, NRS 2(1,4)(4.088,<0.001) at week 8, NRS 1(0,2)(4.206,<0.001) at week 12, NRS 2(0,2)(4.222,<0.001) at week 16, DLQI (13.83±5.71) at baseline, DLQI (8.00±4.02)(=6.325,<0.001) at week 4, DLQI (5.61±3.50)(=8.060,<0.001) at week 8, DLQI (3.96±1.99)(=8.717,<0.001) at week 12, DLQI (2.70±1.89)(=10.355,<0.001) at week 16, POEM (18.04±6.41) at baseline, POEM (9.70±4.70)(=7.031,<0.001) at week 4, POEM (7.74±3.48)(=8.806,<0.001) at week 8, POEM (6.35±3.33)(=10.474,<0.001) at week 12, POEM (4.26±2.51)(=11.996,<0.001) at week 16. In the 16th week, 100%(23 patients), 91.3%(21 patients), 34.8%(8 patients) and 8.7%(2 patients) of 23 patients reached SCORAD30, SCORAD50, SCORAD70, and SCORAD90 statuses, respectively. There were 82.6%(19 patients), 95.7%(22 patients) and 95.7%(22 patients) of 23 patients with NRS, DLQI and POEM improved by≥4 points compared with baseline. Twelve patients with AD who continued to receive dupilumab after 16 weeks showed further improvement in skin lesions. The adverse events were conjunctivitis and injection site reaction. In conclusion, dupilumab is an effective and safe treatment for moderate and severe AD. However, the longer-term efficacy and safety require further studies involving larger sample sizes and a longer follow-up time.